| abstract |
(57) The present invention relates to a compound of the formula (I) wherein R is a 5-membered heteroaryl group having 3 or 4 nitrogen heteroatoms, wherein the quinoxalinedione is represented by a ring carbon or a nitrogen atom. A group attached to a ring or a 6-membered heteroaryl group having 1 to 3 nitrogen heteroatoms, wherein the group is attached to a quinoxalinedione ring by a ring carbon atom. There, both said group, optionally and optionally benzofused, optionally, including in the benzo-fused portion, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 3 -C 7 cycloalkyl, halo , hydroxy, C 1 -C 4 alkoxy, C 3 -C 7 cycloalkyl alkyloxy, -COOH, C 1 -C 4 alkoxycarbonyl, -CONR 3 R 4, -NR 3 R 4, -S (O) p (C 1 -C 4 alkyl), —SO 2 NR 3 R 4 , aryl, aryloxy, aryl (C 1 -C 4 ) alkoxy and het are each independently substituted with one or two substituents selected from the above-mentioned C 1- C 4 alkyl, optionally, C 3 -C 7 cycloalkyl, halo, hydroxy, C 1 -C 4 alkoxy, halo (C 1 -C 4) alkoxy, C 3 -C 7 (O) p (C 1 - C 4 alkyl), - SO 2 (aryl), - SO 2 NR 3 R 4, morpholino, aryl, aryloxy, aryl (C 1 -C 4) substituted by alkoxy or het, and said C 2 -C 4 alkenyl is optionally substituted with aryl; R 1 and R 2 are each independently H, fluoro, chloro, bromo, C 1 -C 4 alkyl and halo (C 1 -C 4 ) alkyl Choose from R 3 and R 4 are each independently selected from H and C 1 -C 4 alkyl or, taken together, are C 5 -C 7 alkylene; and p is 0, 1 or 2) and their pharmaceutically acceptable salts, along with the preparation of such compounds, compositions containing them, their use, and intermediates used in their synthesis. . The compounds are useful as NMDA receptor antagonists for treating acute neurodegenerative disorders and chronic neuropathies. |